Therapeutic Strategies in Pulmonary Hypertension of the Newborn: Where Are We Now?

被引：12

作者：

Sanchez Luna, Manuel ^{[1
]}

Luisa Franco, Ma ^{[1
]}

Bernardo, Belen ^{[1
]}

机构：

[1] Univ Complutense Madrid, Hosp Gen Univ Gregorio Maranon, Neonatal Intens Care Unit, Div Neonatol, Madrid 28009, Spain

来源：

CURRENT MEDICINAL CHEMISTRY | 2012年 / 19卷 / 27期

关键词：

PPHN; newborn; HFOV; iNO; sildenafil; ECMO; INHALED NITRIC-OXIDE; CONGENITAL DIAPHRAGMATIC-HERNIA; EXTRACORPOREAL MEMBRANE-OXYGENATION; MECONIUM ASPIRATION SYNDROME; HYPOXEMIC RESPIRATORY-FAILURE; HIGH-FREQUENCY VENTILATION; CHRONIC LUNG-DISEASE; END-EXPIRATORY PRESSURE; INTRAVENOUS SILDENAFIL; STRUCTURAL BASIS;

D O I：

10.2174/092986712803306475

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Despite recent advances, Persistent Pulmonary Hypertension of the Newborn (PPHN) still represents an important challenge for neonatologists. The care of newborns with PPHN requires meticulous therapeutic and ventilation strategies including, besides the stabilization of the newborn, the use of selective pulmonary vasodilators as inhaled Nitric Oxide (iNO). However, not all the neonates with PPHN are responsive to this clinical approach. Recent studies have proposed the use of alternative therapies to iNO, when it is not available, or there is no or only a transitory response. Sildenafil, a phosphodiesterase 5 inhibitor, appears as a frequent used therapy in refractory forms of PPHN. The aim of this review is to analyze the current therapeutic strategies in PPHN with special emphasis on iNO.

引用

页码：4640 / 4653

页数：14

共 50 条

[1] Pulmonary hypertension and the serotonin hypothesis: where are we now?
MacLean, M. R.
[J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 : 27 - 31
[2] Therapeutic strategies in persistent pulmonary hypertension of the newborn
Greenough, A
[J]. PROGRESS IN PEDIATRIC CARDIOLOGY, 1998, 9 (02) : 69 - 72
[3] Therapeutic strategies for social anxiety disorder: where are we now?
Pelissolo, Antoine
Abou Kassm, Sandra
Delhay, Lauriane
[J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (12) : 1179 - 1189
[4] Pulmonary hypertension in autoimmune rheumatic diseases - Where are we now?
Magliano, M
Isenberg, DA
Hillson, J
[J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (08): : 1997 - 2009
[5] Microbiome and hypertension: where are we now?
Vallianou, Natalia G.
Geladari, Eleni
Kounatidis, Dimitris
[J]. JOURNAL OF CARDIOVASCULAR MEDICINE, 2020, 21 (02) : 83 - 88
[6] Newborn screening for SCID: where are we now?
Buelow, Becky J.
Routes, John M.
Verbsky, James W.
[J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (12) : 1649 - 1657
[7] STRUCTURES AND STRATEGIES - WHERE ARE WE NOW
BROADBENT, D
[J]. PSYCHOLOGICAL RESEARCH-PSYCHOLOGISCHE FORSCHUNG, 1987, 49 (2-3): : 73 - 79
[8] Pulmonary haemodynamics and pulmonary congestion: where are we now?
Bart, Nicole K.
Kotlyar, Eugene
Keogh, Anne M.
[J]. EUROPEAN HEART JOURNAL, 2022, 43 (42) : 4515 - 4515
[9] Idiopathic intracranial hypertension - Where are we now?
Thurtell, Matthew
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
[10] Newborn screening and renal disease: where we have been; where we are now; where we are going
Merritt, J. Lawrence, II
Askenazi, David
Hahn, Si Houn
[J]. PEDIATRIC NEPHROLOGY, 2012, 27 (09) : 1453 - 1464

← 1 2 3 4 5 →